The Team
We are driven by our Vision – To improve the Quality of Life for couples facing infertility around the world.
Management
John Lempert
Chief Executive Officer
John Lempert studied law at Lund University and is by the National Board of Health and Welfare a certified dental technician. John has among other worked for Johnson & Johnson in international positions and in smaller entrepreneurial companies being responsible for developing new patented dental materials from development, through regulatory affairs and manufacturing to completed market entry and build-up.
John has also had assignments for the World Bank and has more than 35 years of experience from business development in the medtech industry.
Employee since: 2020
Other current assignments: ABD Nordic AB, board member. PC Medicus AB, board member.
Shares: 140 284 direct
TO1: 35 524 direct
Options: 162 000 direct
Kushagr Punyani
Chief Scientific Officer
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Employee since: 2018
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member.
Shares: 1 578 240 direct
Options: None
Cajsa Wramdemark
Chief Financial Officer
Cajsa Wramdemark, owner and founder of More than Finance AB, holds a Master of Science in International Business Administration and Economics from the School of Economics and Management, Lund University.
Cajsa has more than 20 years of experience within finance in both multi-national as well as SME companies within Life Science as well as other areas. She has had roles as CFO and Chief Accounting Manager. In addition to finance, Cajsa has been responsible for HR and Purchasing in previous roles.
Employee since: 2021
Other current assignments: More than Finance in Sweden AB, board member and CEO.
Shares: 12 876 direct
TO1: 12 876 direct
Options: None
Staff
Chemutai Beatrice
Project Manager
Chemutai holds a Master of Science in International Development & Management from Lund University. She has over 5 years of experience working with Lean and Agile Project Management Methodologies and has been actively involved in planning and executing innovative project management solutions for companies in retail and information technology industries. Her project management experience spans across B2B and D2C business models, localization, customer experience, user-centred design strategy and growth marketing.
Shares: 5 328 direct
TO1: 5 328 direct
Thabitha Carlsson
QA / RA Manager
Thabitha, a licenced Pharmacist, holds a Bachelor’s degree in Pharmacy from University of the North and Uppsala University, studies in Pharmacovigilance and Clinical Trials, Uppsala and Gothenburg Universities and a Master in Business Administration, MANCOSA.
Thabitha has 13 years quality management experience both in Sweden and South Africa, within the pharmacy sector. She has had roles as a Responsible Pharmacist and worked with Regulatory issues in the hospital and medical device sectors.
Shares: 6 000 direct
TO1: 6 000 direct
Options: None
Jaime Castillo-León
Technical Affairs Manager
Jaime Castillo-León studied chemistry at the Universidad Industrial de Santander. Jaime holds a Ph.D. in electrochemistry from Lund University. He has more than 15 years of industrial and academic experience designing and fabricating electrochemical and optical biosensors, besides solar energy devices. He has held Director and Managerial offices in two Swedish SMEs in the fields of biomedical and solar energy, as well as the position of Associate Professor at DTU Nanotech, Technical University of Denmark.
Board of Directors
Eva Nilsagård
Chairman of the board
Board member since: 2020
Born: 1964
Main occupation: Board professional
Shares: 30 000 direct
Options: 81 000 direct
Eva Nilsagård is currently the founder and CEO of Nilsagård Consulting AB. Eva holds an executive MBA in business management and organization as well as a master’s degree in accounting and finance from the Gothenburg School of Economics. Eva has been CFO at OptiGroup, Vitrolife and Plastal, SVP Strategy & Business development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva has a long experience of listed companies and over 10 years of experience as a mentor for young female managers.
Other current assignments: Nimbus Group AB, board member. Hansa Biopharma AB (publ), board member. Xbrane Biopharma AB, board member. Aktiebolaget Svensk Exportkredit, board member. IRRAS AB, board member. Addlife AB, board member. Bufab AB (publ), board member. Nilsagård Consulting AB, board member and CEO.
Ingela Liljeqvist Soltic
Board member
Board member since: 2019
Born: 1967
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Shares: None
Options: None
Dr. Ingela Liljeqvist Soltic currently works as an embryologist and unit manager for laboratory and tissue establishment at the Center for Reproductive Medicine (RMC) at Skåne University Hospital. Ingela has a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science.Ingela has previously worked as an embryologist at IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience from IVF and fertility issues.
John Moll
Board member
Board member since: 2020
Born: 1978
Main occupation: Investor and entrepreneur
Shares: 231 066 direct and via company
TO1: 75 066 direct and via company
Options: None
John Moll is the founder of Torna Kapital AB, through which he invests in development companies. John has conducted studies in finance at Lund University and master´s studies in biotechnology at Lund University. John has a long experience as an entrepreneur and has founded and sold two companies, including in the health and pharmaceutical sector. As an experienced Lund-based investor, John has a wide network of contacts in the Öresund region.
Other current assignments: Aktiebolaget Lundgren, Nilsson & Moll, board member. Carbiotix AB (publ), board member. Qlife Holding AB (publ), board member. Qlife Aps, board member. Huskvarna Stadshotell AB, board member. Town&Country Resorts AB, board member. Acantor Holding AB, board member. Torna Kapital AB, board member.
Sören Melsing Frederiksen
Board member
Board member since: 2020
Born: 1976
Main occupation: VP Sales & Marketing Galenica AB
Shares: 220 132 via company
TO1: 169 132 via company
Options: 27 000 direct
Sören Melsing Frederiksen currently holds the position of Vice President, Generics and Commercial Rx, ORIFARM GROUP A/S. Søren holds a B.A.Sc in Applied Science and a master´s degree in drug development. Søren has held several positions within LEO Pharma and as commercial manager for the Nordic region at Aspen Pharma. Søren has extensive experience in marketing and sales as well as the entire value chain in the pharmaceutical industry.
Other current assignments: VBM Ejendomsselkabet af 2007 Aps, board member. BotSupply ApS, board member. StenoCare A/S, board member. SML Holding ApS, board member and CEO. VBM LaboratorietA/S, board member.
Kushagr Punyani
Board member
Board member since: 2018
Born: 1991
Main occupation: CSO Spermosens AB
Shares: 1 578 240 direct
Options: None
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member.
Development Partners
Zimmer & Peacock
Z&P is a valued partner in Spermosens Development Team on the development of a disposable chip for the rapid assessment of male fertility based on Spermosens’ IP around the direct measurement of spermatozoa within the semen, and prediction of the fusion capacity to the oocyte (egg cell).
Z&P has deep knowledge in, and experience from, the development of electrochemical biosensors, and these capabilities are being leveraged by Spermosens to deliver a product to the market, in an investment efficient manner, leveraging capital insertion with ROI.
Spermosens understanding of the fertility market, and the patent pending platform technology will supply the answer to solving problems within the IVF market. Spermosens male-fertility diagnostic products are expected to lead to fewer cycles performed to fertilisation and conception.
…we are thrilled to be selected as a trusted development partner with Spermosens and delighted to be guided by Spermosens mission . We are impressed by Spermosens break-through technology and their go-to-market strategy.
– Z&P CEO Mr. Even Zimmer
Read more at: zimmerpeacock.com
IP Management
HØIBERG
Stefan has a broad interdisciplinary background from his undergraduate studies at the nanoengineering program, and subsequent PhD studies in Physics at Lund University, Sweden. Throughout his PhD he focused on the application of nano and microstructures for the analysis of particles, for the investigation of biological samples. In addition Stefan has an extensive knowledge about miniaturization of diagnostic devices for lab-on-chip applications.
The profound technical background has been a perfect match for Spermosens, and has been an instrumental component when Stefan and his colleagues at the renowned patent law firm HØIBERG, have developed a viable IP strategy on behalf of Spermosens. The Spermosens and HØIBERG teams work closely together to maintain and develop the patent portfolio of Spermosens.
Peter Holm is a European Patent Attorney, Partner and Country Manager for Sweden at the patent law firm HØIBERG. Together with Stefan Holm Nygaard, Peter is acting as Spermosens’ strategic IP advisor. Peter has a PhDin Biochemistry and Biophysics from Karolinska Institutet, Sweden and has been working as a patent attorney at HØIBERG since 2006, assisting startup companies and individual researchers within the lifescience field, with the development of their IP strategy.
Read more at: hoiberg.com
Case responsible attorney for the Spermosens patent portfolio.
